Log in Free sign up

BiomX (PHGE) News and press releases

News

From Benzinga Pro

BiomX Announces Dosing Of The First Two Patients In Phase 1b/2a Study Of BX004 For Treatment Of Chronic Respiratory Infections In Patients With Cystic Fibrosis

Biotech, News, FDA, General

BiomX Inc. (NYSE:PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Friday's trading, 69 companies set new 52-week lows.

Chardan Capital Maintains Buy on BiomX, Lowers Price Target to $6

News, Price Target, Analyst Ratings

Chardan Capital analyst Keay Nakae maintains BiomX (AMEX:PHGE) with a Buy and lowers the price target from $10 to $6.

The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures

Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed

Biotech, Earnings, News, Penny Stocks, Guidance, Health Care, Movers, Trading Ideas, General

BiomX Announces Publication In The Journal, Bioinformatics

BiomX Announces Publication in the Journal, Bioinformatics Development of Exodus Algorithm Overcomes Limitations in Identifying and Quantifying the Genomes of Genetically Related Microorganisms BiomX Inc. (NYSE:PHGE)

Ladenburg Thalmann Maintains Buy on BiomX, Lowers Price Target to $8

News, Price Target, Analyst Ratings

Ladenburg Thalmann analyst Michael Higgins maintains BiomX (AMEX:PHGE) with a Buy and lowers the price target from $13 to $8.

Earnings Scheduled For May 11, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

103 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Earnings Scheduled For March 30, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021.

Press releases

From Benzinga Pro

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

Data Readout from Part I of the Study Expected in 3Q 2022 BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target

BiomX Announces Corporate Restructuring

Reducing headcount by 50% to further extend capital resources Cash runway extended to at least mid-2024 Cystic Fibrosis Program remains on track with initial readout from Phase 1b/2a study of BX004 expected in the

BiomX Announces Publication in the Journal, Bioinformatics

Development of Exodus Algorithm Overcomes Limitations in Identifying and Quantifying the Genomes of Genetically Related Microorganisms BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

Upcoming KOL Webinar Scheduled for May 12th to Discuss BX004 in Cystic Fibrosis IND Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis Cash Runway Through Multiple Data

BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

Live Webinar Event to be Held on Thursday, May 12th, 11:00 AM EDT BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that

BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Expecting Readouts from Part I of the Phase 1b/2a Cystic Fibrosis Study in the Third Quarter of 2022 and the Phase 1/2 Atopic Dermatitis Study in the Fourth Quarter of 2022 Strong Balance Sheet with Cash Runway Through